Agreement signedPublished 2 Mar 2026

Candid Therapeutics /
Rallybio

Candid Therapeutics agrees to buy Rallybio

Buy side: Candid Therapeutics
Buy sideCandid Therapeutics
Target: Rallybio
TargetRallybio
Rallybio Corp · 2 Mar 2026Source
Buy side: Candid Therapeutics
Buy sideCandid Therapeutics
Target: Rallybio
TargetRallybio
01 / BuyerCandid Therapeutics
02 / TargetRallybio
Source for the buyer and target: Rallybio Corp

For the buyer and target.

“On March 1, 2026, Rallybio Corporation, a Delaware corporation (“ Rallybio ”), entered into an Agreement and Plan of Merger and Reorganization (the “ Merger Agreement ”) with Candid Therapeutics, Inc., a Delaware corporation (“ Candid ”), a clinical-stage biotechnology company advancing a leading portfolio of T-cell engager (TCE) therapeutics for autoimmune diseases, and Farmington Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of Rallybio (“ Merger Sub ”).”

Published 2 Mar 2026

Open the source
01

What happened

Candid Therapeutics agreed to acquire Rallybio, according to a filing dated March 2, 2026. [01]

02

The source

Everything on this page comes from the source below, quoted word for word.

01
Source · Rallybio Corp

Candid Therapeutics agrees to buy Rallybio

This document is the source for the companies, stage and people on this page.

Open the source
03

Timeline

Every date the source states, in order, each with the words it comes from. Anything marked ahead is a target the source gives, not something that has happened.

  1. Announced

    “Candid Therapeutics agrees to buy Rallybio Candid Therapeutics agreed to acquire Rallybio, according to a filing dated March 2, 2026”

    Open the source
  2. Published by Rallybio Corp

    The source this page is built from.

    Open the source

The same firms, in other deals

The firms' deal history and connections across other deals.

These firms' full profiles are part of Pro.

Get ProAlready a member? Sign in

Pro is open to everyone.